Intra-operative Pancreatoscopy in Patients With IPMN
← catalyst calendarSponsored by Boston Scientific Corporation (industry) · BSX — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
100actual
Sites
8
Countries
China, India, Japan +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-03-20 | actual | When the study began enrolling |
| Primary completion | 2022-08-11 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | May 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2018-11-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Intraductal Papillary Mucinous Neoplasm
Intervention
- Device: SpyGlass
Primary outcome
what the primary-completion date above is the date OFRate of detection of discontinuous (skip) lesions along the main pancreatic duct
measured During index procedure
Publications
- PMID 41890524 — linked by the registry
- PMID 38277399 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · BSX's whole pipeline · Catalyst calendar · Every registered study · What changed